



## Clinical trial results:

### A Phase 2, Open-label, Multicenter Study to Assess Safety and Efficacy of Second/Third-line

### Treatment with nab®-Paclitaxel1 (ABI-007) in Combination with Epigenetic Modifying Therapy

### of CC-486, or Immunotherapy of Durvalumab (MEDI4736), or as Monotherapy in Subjects with

### Advanced Non-small Cell Lung Cancer (NSCLC): ABOUND.2L+

#### Summary

EudraCT number	2014-001105-41
Trial protocol	ES IT DE FR
Global end of trial date	17 August 2023

#### Results information

Result version number	v1 (current)
This version publication date	31 August 2024
First version publication date	31 August 2024

#### Trial information

##### Trial identification

Sponsor protocol code	ABI-007-NSCL-006
-----------------------	------------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 November 2019
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	17 August 2023
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

Assess efficacy and safety of:

- o nab-paclitaxel in combination with epigenetic modifying therapy of CC-486,
- o nab-paclitaxel in combination with immunotherapy of durvalumab,
- o and nab-paclitaxel monotherapy

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 January 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Canada: 8
Country: Number of subjects enrolled	France: 20
Country: Number of subjects enrolled	Germany: 21
Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Spain: 103
Country: Number of subjects enrolled	United Kingdom: 46
Country: Number of subjects enrolled	United States: 32
Worldwide total number of subjects	240
EEA total number of subjects	154

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	123
From 65 to 84 years	117
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Eligible participants included those with advanced non-small cell lung cancer who had received no more than one prior containing chemotherapy regimen. Immunotherapy as a prior line of treatment was allowed. Randomization was stratified by eastern cooperative oncology group performance status, gender and the smoking status of the participant.

### Period 1

Period 1 title	Pre-treatment
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	Nab-Paclitaxel + CC-486
------------------	-------------------------

Arm description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by intravenous (IV) infusion over 30 minutes on Days 8 and 15. CC-486 200 mg tablets on Days 1 to 14 of each 21-day treatment cycle until disease progression (DP), development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Arm type	Experimental
Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

100 mg/m<sup>2</sup> over 30 minutes on Days 8 and 15

Investigational medicinal product name	Azacitidine
Investigational medicinal product code	CC-486
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg on Days 1 to 14 of each 21-day cycle

<b>Arm title</b>	Nab-Paclitaxel + Durvalumab
------------------	-----------------------------

Arm description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8. Durvalumab (durva) 1125 mg/m<sup>2</sup> by IV infusion over 1 hour on Day 15 of each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Arm type	Experimental
Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:	
1125 mg/m <sup>2</sup> over 1 hour on Day 15 of each 21-day cycle	
Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
100 mg/m <sup>2</sup> over 30 minutes on Days 1 and 8	
<b>Arm title</b>	Nab-Paclitaxel
Arm description:	
Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8 each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	
Arm type	Experimental
Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use
Dosage and administration details:	
100 mg/m <sup>2</sup> over 30 minutes on Days 1 and 8	

Number of subjects in period 1	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel
Started	81	79	80
Completed	79	78	79
Not completed	2	1	1
Other reasons	2	1	1

<b>Period 2</b>	
Period 2 title	Treatment
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded
<b>Arms</b>	
Are arms mutually exclusive?	Yes
<b>Arm title</b>	Nab-Paclitaxel + CC-486
Arm description:	
Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by intravenous (IV) infusion over 30 minutes on Days 8 and 15. CC-486 200 mg tablets on Days 1 to 14 of each 21-day treatment cycle until disease progression (DP), development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	
Arm type	Experimental

Investigational medicinal product name	Azacitidine
Investigational medicinal product code	CC-486
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

200 mg on Days 1 to 14 of each 21-day cycle

Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

100 mg/m<sup>2</sup> over 30 minutes on Days 8 and 15

<b>Arm title</b>	Nab-Paclitaxel + Durvalumab
------------------	-----------------------------

Arm description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8. Durvalumab (durva) 1125 mg/m<sup>2</sup> by IV infusion over 1 hour on Day 15 of each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Arm type	Experimental
Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

100 mg/m<sup>2</sup> over 30 minutes on Days 1 and 8

Investigational medicinal product name	Durvalumab
Investigational medicinal product code	MEDI4736
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

1125 mg/m<sup>2</sup> over 1 hour on Day 15 of each 21-day cycle

<b>Arm title</b>	Nab-Paclitaxel
------------------	----------------

Arm description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8 each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Arm type	Experimental
Investigational medicinal product name	Nab-Paclitaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

100 mg/m<sup>2</sup> over 30 minutes on Days 1 and 8

<b>Number of subjects in period 2</b>	<b>Nab-Paclitaxel + CC-486</b>	<b>Nab-Paclitaxel + Durvalumab</b>	<b>Nab-Paclitaxel</b>
Started	79	78	79
Entered Extension Phase	0	4	0
Completed	0	0	0
Not completed	79	78	79
Adverse event, serious fatal	1	13	2
Consent withdrawn by subject	11	6	4
Adverse event, non-fatal	8	8	9
Progressive Disease	42	40	47
Other reasons	8	7	7
Symptomatic Deterioration	9	4	10

## Baseline characteristics

### Reporting groups

Reporting group title	Nab-Paclitaxel + CC-486
-----------------------	-------------------------

Reporting group description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by intravenous (IV) infusion over 30 minutes on Days 8 and 15. CC-486 200 mg tablets on Days 1 to 14 of each 21-day treatment cycle until disease progression (DP), development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Reporting group title	Nab-Paclitaxel + Durvalumab
-----------------------	-----------------------------

Reporting group description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8. Durvalumab (durva) 1125 mg/m<sup>2</sup> by IV infusion over 1 hour on Day 15 of each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Reporting group title	Nab-Paclitaxel
-----------------------	----------------

Reporting group description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8 each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Reporting group values	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel
Number of subjects	81	79	80
Age categorical			
Units:			

Age Continuous			
Units: years			
arithmetic mean	64.0	62.7	62.6
standard deviation	± 9.00	± 10.74	± 9.58
Sex: Female, Male			
Units: participants			
Female	31	25	30
Male	50	54	50
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	2
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	1	2
White	67	77	63
More than one race	0	0	0
Unknown or Not Reported	14	1	13
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	1	6	3
Not Hispanic or Latino	67	73	66
Unknown or Not Reported	13	0	11

Reporting group values	Total		
------------------------	-------	--	--



Number of subjects	240		
Age categorical			
Units:			
Age Continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male			
Units: participants			
Female	86		
Male	154		
Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0		
Asian	2		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	3		
White	207		
More than one race	0		
Unknown or Not Reported	28		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	10		
Not Hispanic or Latino	206		
Unknown or Not Reported	24		

## End points

### End points reporting groups

Reporting group title	Nab-Paclitaxel + CC-486
Reporting group description: Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by intravenous (IV) infusion over 30 minutes on Days 8 and 15. CC-486 200 mg tablets on Days 1 to 14 of each 21-day treatment cycle until disease progression (DP), development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	
Reporting group title	Nab-Paclitaxel + Durvalumab
Reporting group description: Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8. Durvalumab (durva) 1125 mg/m <sup>2</sup> by IV infusion over 1 hour on Day 15 of each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	
Reporting group title	Nab-Paclitaxel
Reporting group description: Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8 each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	
Reporting group title	Nab-Paclitaxel + CC-486
Reporting group description: Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by intravenous (IV) infusion over 30 minutes on Days 8 and 15. CC-486 200 mg tablets on Days 1 to 14 of each 21-day treatment cycle until disease progression (DP), development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	
Reporting group title	Nab-Paclitaxel + Durvalumab
Reporting group description: Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8. Durvalumab (durva) 1125 mg/m <sup>2</sup> by IV infusion over 1 hour on Day 15 of each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	
Reporting group title	Nab-Paclitaxel
Reporting group description: Participants received nab-paclitaxel 100 mg/m <sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8 each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.	

### Primary: Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator

End point title	Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator
End point description: Progression-free survival was defined as the time in months from the date of randomization/assignment to the date of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria documented by computed tomography (CT) scan, not including symptomatic deterioration, or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. Participants who did not have disease progression and had not died, regardless of whether they were discontinued from treatment, were censored at the date of last tumor assessment, on or prior to the clinical cut-off date that the participant was progression free. Progressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions from nadir.	
End point type	Primary
End point timeframe: From date of first dose of IP to DP; up to data cut-off date of 30 August (Aug) 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 December (Dec) 2017 for Durva + nab-paclitaxel; participants were followed for PFS for up to 18 months	

<b>End point values</b>	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	81	79	80	
Units: months				
median (confidence interval 95%)	3.2 (2.30 to 4.30)	4.5 (3.45 to 5.88)	4.2 (2.79 to 5.06)	

## Statistical analyses

<b>Statistical analysis title</b>	Hazard Ratio (HR)
Statistical analysis description: Based on stratified Cox proportional hazards regression model.	
Comparison groups	Nab-Paclitaxel + CC-486 v Nab-Paclitaxel
Number of subjects included in analysis	161
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.9
upper limit	1.94

## Secondary: Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST V 1.1 Criteria

End point title	Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST V 1.1 Criteria
-----------------	---

### End point description:

Overall Response was defined as percentage of participants who achieved a radiologic confirmed complete response or partial response according to RECIST V 1.1 criteria and compared with baseline among all tumor assessments, where baseline was the last CT obtained prior to or on Day 1 of treatment. Per RECIST V 1.1 criteria, a CR is defined as a disappearance of all target lesions; a PR is defined as having at least a 30% decrease in the sum of diameters of target lesions from baseline. Responses were evaluated every 6 weeks.

End point type	Secondary
----------------	-----------

### End point timeframe:

Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

End point values	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	81	79	80	
Units: percentage of participants				
number (confidence interval 95%)	13.6 (7.0 to 23.0)	27.8 (18.3 to 39.1)	16.3 (8.9 to 26.2)	

## Statistical analyses

Statistical analysis title	Overall Response Rate Ratio
Comparison groups	Nab-Paclitaxel + CC-486 v Nab-Paclitaxel
Number of subjects included in analysis	161
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Overall Response Rate Ratio
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.398
upper limit	1.754

## Secondary: Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to RECIST V 1.1 Criteria

End point title	Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to RECIST V 1.1 Criteria
-----------------	---

### End point description:

Disease control rate was defined as the percentage of participants who had a CR, PR or SD during the course of the study, according to RECIST version 1.1 criteria, as evaluated by the investigator. RECIST Version 1.1 criteria is defined as follows: - Complete Response is the disappearance of all target lesions; - Partial Response is at least a 30% decrease in the sum of diameters of target lesions from baseline; - Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. Responses were evaluated every 6 weeks.

End point type	Secondary
----------------	-----------

### End point timeframe:

Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

End point values	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	81	79	80	
Units: Percentage of Participants				
number (confidence interval 95%)	65.4 (54.0 to 75.7)	70.9 (59.6 to 80.6)	67.5 (56.1 to 77.6)	

## Statistical analyses

<b>Statistical analysis title</b>	Disease Control Rate Ratio
Comparison groups	Nab-Paclitaxel + CC-486 v Nab-Paclitaxel
Number of subjects included in analysis	161
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Disease Control Rate Ratio
Point estimate	0.97
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.778
upper limit	1.207

## Secondary: Kaplan Meier Estimate of Overall Survival (OS)

End point title	Kaplan Meier Estimate of Overall Survival (OS)
End point description: Overall survival was defined as the time in months between randomization/treatment assignment and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact. 99999=NA	
End point type	Secondary
End point timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; participants were followed for overall survival up to 30 months	

<b>End point values</b>	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	81	79	80	
Units: Months				
median (confidence interval 95%)	8.1 (6.64 to 11.86)	10.1 (7.75 to 99999)	17.0 (8.21 to 99999)	

## Statistical analyses

<b>Statistical analysis title</b>	Hazard Ratio (HR)
Statistical analysis description: Based on stratified Cox proportional hazards regression model.	
Comparison groups	Nab-Paclitaxel + CC-486 v Nab-Paclitaxel
Number of subjects included in analysis	161
Analysis specification	Pre-specified
Analysis type	
Parameter estimate	Hazard ratio (HR)
Point estimate	1.7
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.08
upper limit	2.57

### Secondary: Number of Participants with Treatment Emergent Adverse Events (TEAEs) During the Entire Treatment Period

End point title	Number of Participants with Treatment Emergent Adverse Events (TEAEs) During the Entire Treatment Period
-----------------	--

End point description:

TEAEs were defined as any adverse event or serious adverse event that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP for Arms A and C or up to 90 days after the last dose for Arm B, and those SAEs made known to the investigator at any time thereafter that are suspected of being related to IP. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild I intervention/therapy required Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death.

End point type	Secondary
----------------	-----------

End point timeframe:

TEAEs were collected up to 4 weeks after receiving last dose of IP for nab-paclitaxel and CC-486 + nab-paclitaxel, and up to 90 days after the last IP dose for Durva + nab-paclitaxel; TEAEs were collected up to 354 weeks

<b>End point values</b>	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	79	78	79	
Units: Participants				
TEAE	79	78	78	
Serious TEAE	30	44	30	
Grade (GR) 3/4 TEAE	48	57	47	
Grade 3 or Higher	49	59	47	
Treatment Related TEAE	74	72	68	
Treatment Related Serious TEAE	11	20	5	
Treatment Related GR 3 or Higher TEAE	32	36	25	
TEAE With Action to Reduce/Interrupt IP	49	59	38	

Treatment-Related to Reduce or Interrupt IP	36	36	27	
TEAE with Action Taken to Withdraw IP	8	11	9	
Drug Related TEAE with Action Taken to Withdraw IP	6	10	9	
TEAE with Fatal Outcome	4	12	3	
Treatment Related TEAE with Fatal Outcome	0	4	1	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Participants Who Discontinued Study Treatment

End point title	Percentage of Participants Who Discontinued Study Treatment
-----------------	---

End point description:

The discontinuation rate was defined as the percentage of participants who had study drug discontinued and was assessed throughout the conduct of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 30 Aug 2017 for CC-486 + nab-paclitaxel and 26 Nov 2019 for nab-paclitaxel and 20 Jul 2023 for Durva + nab-paclitaxel (up to 445 weeks)

End point values	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	79	78	79	
Units: percentage of participants				
number (not applicable)	100.00	100.00	100.00	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Dose Intensity Per Week of Durvalumab

End point title	Dose Intensity Per Week of Durvalumab
-----------------	---------------------------------------

End point description:

Dose intensity was the cumulative dose divided by the dosing period in weeks).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

End point values	Nab-Paclitaxel + Durvalumab			
Subject group type	Reporting group			
Number of subjects analysed	77			
Units: mg/week				
arithmetic mean (standard deviation)	279.96 (± 97.304)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Dose Intensity Per Week of nab-Paclitaxel

End point title	Dose Intensity Per Week of nab-Paclitaxel
End point description: Dose intensity was the cumulative dose divided by the dosing period in weeks.	
End point type	Secondary
End point timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel	

End point values	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	79	78	79	
Units: mg/m <sup>2</sup> /week				
arithmetic mean (standard deviation)	54.73 (± 11.390)	57.18 (± 13.605)	58.61 (± 14.893)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Dose Intensity Per Week of CC-486

End point title	Dose Intensity Per Week of CC-486
End point description: Dose intensity was the cumulative dose divided by the dosing period in weeks.	
End point type	Secondary
End point timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel,	



<b>End point values</b>	Nab-Paclitaxel + CC-486			
Subject group type	Reporting group			
Number of subjects analysed	79			
Units: mg/ week				
arithmetic mean (standard deviation)	716.66 (± 220.945)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Participants With Study Drug Dose Reductions

End point title	Percentage of Participants With Study Drug Dose Reductions
End point description: A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or treatment emergent adverse events or toxicities. 00000= 0 participants analyzed.	
End point type	Secondary
End point timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 26 Nov 2019 for nab-paclitaxel and Durva + nab-paclitaxel (up to 255 weeks)	

<b>End point values</b>	Nab-Paclitaxel + CC-486	Nab-Paclitaxel + Durvalumab	Nab-Paclitaxel	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	79	78	79	
Units: Percentage of Participants				
number (not applicable)				
Nab-Paclitaxel	10.1	14.1	10.1	
CC-486	20.3	00000	00000	
Durvalumab (Reductions Not Allowed per Protocol)	00000	0.0	00000	

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

SAEs and NSAEs were collected up to 4 weeks post last dose of nab-paclitaxel and CC-486+nab-paclitaxel and up to 90 days post last dose of Durva+nab-paclitaxel (Up to 354 weeks). Deaths are from their first dose to study completion (Up to 449 weeks).

Adverse event reporting additional description:

The number at Risk for All-Cause Mortality represents all Randomized Participants. The number at Risk for Serious Adverse Events and Other (Not Including Serious) Adverse Events represents all participants that received at least 1 dose of study medication.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.0
--------------------	------

### Reporting groups

Reporting group title	Nab-Paclitaxel + CC-486
-----------------------	-------------------------

Reporting group description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by intravenous (IV) infusion over 30 minutes on Days 8 and 15. CC-486 200 mg tablets on Days 1 to 14 of each 21-day treatment cycle until disease progression (DP), development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Reporting group title	Nab-Paclitaxel
-----------------------	----------------

Reporting group description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8 each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Reporting group title	Nab-Paclitaxel + Durvalumab
-----------------------	-----------------------------

Reporting group description:

Participants received nab-paclitaxel 100 mg/m<sup>2</sup> by IV infusion over 30 minutes on Days 1 and 8. Durvalumab (durva) 1125 mg/m<sup>2</sup> by IV infusion over 1 hour on Day 15 of each 21-day treatment cycle until disease progression, development of an unacceptable toxicity, death, lost to follow-up, or withdrawal of consent, in accordance with local standard of care.

Serious adverse events	Nab-Paclitaxel + CC-486	Nab-Paclitaxel	Nab-Paclitaxel + Durvalumab
Total subjects affected by serious adverse events			
subjects affected / exposed	30 / 79 (37.97%)	30 / 79 (37.97%)	44 / 78 (56.41%)
number of deaths (all causes)	61	49	48
number of deaths resulting from adverse events	5	3	12
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to meninges			

subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
General physical health deterioration			
subjects affected / exposed	2 / 79 (2.53%)	1 / 79 (1.27%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 1
Performance status decreased			
subjects affected / exposed	2 / 79 (2.53%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	2 / 2	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Sudden death			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Pyrexia			
subjects affected / exposed	3 / 79 (3.80%)	1 / 79 (1.27%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	2 / 5	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Interstitial lung disease			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	4 / 79 (5.06%)	4 / 79 (5.06%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 4	0 / 4	1 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	2 / 79 (2.53%)	4 / 79 (5.06%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pulmonary embolism			
subjects affected / exposed	3 / 79 (3.80%)	1 / 79 (1.27%)	3 / 78 (3.85%)
occurrences causally related to treatment / all	0 / 3	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Pneumothorax spontaneous			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Pulmonary haemorrhage			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 2
Respiratory distress			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	3 / 78 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood glucose increased			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood sodium decreased			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Liver function test abnormal subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
White blood cell count increased subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Postoperative fever			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural pneumothorax			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Paraparesis			

subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 79 (0.00%)	2 / 79 (2.53%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Balance disorder			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphasia			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			

subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Retinal vasculitis			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Flatulence			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	1 / 79 (1.27%)	1 / 79 (1.27%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Vomiting			
subjects affected / exposed	2 / 79 (2.53%)	1 / 79 (1.27%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	2 / 2	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	2 / 79 (2.53%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Duodenal obstruction			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal ischaemia			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enterocutaneous fistula			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis microscopic			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Acute kidney injury			
subjects affected / exposed	1 / 79 (1.27%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysuria			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anuria			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Adrenal insufficiency			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	3 / 78 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	3 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Back pain			
subjects affected / exposed	2 / 79 (2.53%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Muscular weakness			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone pain			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal wall abscess			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Lung infection			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			

subjects affected / exposed	1 / 79 (1.27%)	1 / 79 (1.27%)	3 / 78 (3.85%)
occurrences causally related to treatment / all	0 / 1	1 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	5 / 79 (6.33%)	3 / 79 (3.80%)	9 / 78 (11.54%)
occurrences causally related to treatment / all	2 / 5	1 / 3	2 / 9
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 2
Pneumonia pneumococcal			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	2 / 79 (2.53%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Urinary tract infection			
subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	2 / 78 (2.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Clostridium difficile colitis			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhinovirus infection			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic infection			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Empyema			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Decreased appetite			

subjects affected / exposed	1 / 79 (1.27%)	0 / 79 (0.00%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic alkalosis			
subjects affected / exposed	0 / 79 (0.00%)	1 / 79 (1.27%)	0 / 78 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Nab-Paclitaxel + CC-486	Nab-Paclitaxel	Nab-Paclitaxel + Durvalumab
Total subjects affected by non-serious adverse events			
subjects affected / exposed	77 / 79 (97.47%)	75 / 79 (94.94%)	75 / 78 (96.15%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	2 / 79 (2.53%)	4 / 79 (5.06%)	9 / 78 (11.54%)
occurrences (all)	2	4	9
Vascular disorders			
Hypotension			
subjects affected / exposed	2 / 79 (2.53%)	4 / 79 (5.06%)	4 / 78 (5.13%)
occurrences (all)	2	4	6
Flushing			
subjects affected / exposed	1 / 79 (1.27%)	4 / 79 (5.06%)	0 / 78 (0.00%)
occurrences (all)	1	4	0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	10 / 79 (12.66%)	7 / 79 (8.86%)	13 / 78 (16.67%)
occurrences (all)	12	7	19
Oedema peripheral			

subjects affected / exposed	12 / 79 (15.19%)	15 / 79 (18.99%)	13 / 78 (16.67%)
occurrences (all)	12	16	14
Non-cardiac chest pain			
subjects affected / exposed	3 / 79 (3.80%)	5 / 79 (6.33%)	6 / 78 (7.69%)
occurrences (all)	3	6	8
General physical health deterioration			
subjects affected / exposed	4 / 79 (5.06%)	1 / 79 (1.27%)	4 / 78 (5.13%)
occurrences (all)	4	1	4
Fatigue			
subjects affected / exposed	24 / 79 (30.38%)	23 / 79 (29.11%)	22 / 78 (28.21%)
occurrences (all)	27	28	31
Chills			
subjects affected / exposed	0 / 79 (0.00%)	4 / 79 (5.06%)	2 / 78 (2.56%)
occurrences (all)	0	5	3
Asthenia			
subjects affected / exposed	26 / 79 (32.91%)	25 / 79 (31.65%)	36 / 78 (46.15%)
occurrences (all)	36	31	49
Respiratory, thoracic and mediastinal disorders			
Productive cough			
subjects affected / exposed	3 / 79 (3.80%)	5 / 79 (6.33%)	11 / 78 (14.10%)
occurrences (all)	4	5	15
Pleural effusion			
subjects affected / exposed	6 / 79 (7.59%)	1 / 79 (1.27%)	2 / 78 (2.56%)
occurrences (all)	7	2	2
Haemoptysis			
subjects affected / exposed	4 / 79 (5.06%)	6 / 79 (7.59%)	6 / 78 (7.69%)
occurrences (all)	5	6	11
Epistaxis			
subjects affected / exposed	3 / 79 (3.80%)	7 / 79 (8.86%)	5 / 78 (6.41%)
occurrences (all)	3	9	6
Dyspnoea			
subjects affected / exposed	16 / 79 (20.25%)	22 / 79 (27.85%)	23 / 78 (29.49%)
occurrences (all)	19	25	27
Cough			

subjects affected / exposed occurrences (all)	16 / 79 (20.25%) 19	23 / 79 (29.11%) 30	22 / 78 (28.21%) 35
Rhinorrhoea subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	3 / 79 (3.80%) 3	4 / 78 (5.13%) 4
Pulmonary embolism subjects affected / exposed occurrences (all)	7 / 79 (8.86%) 7	2 / 79 (2.53%) 2	2 / 78 (2.56%) 2
Pneumonitis subjects affected / exposed occurrences (all)	1 / 79 (1.27%) 1	1 / 79 (1.27%) 1	5 / 78 (6.41%) 5
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	9 / 79 (11.39%) 10	8 / 79 (10.13%) 8	5 / 78 (6.41%) 5
Depressed mood subjects affected / exposed occurrences (all)	0 / 79 (0.00%) 0	1 / 79 (1.27%) 1	4 / 78 (5.13%) 4
Anxiety subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 5	4 / 79 (5.06%) 4	2 / 78 (2.56%) 2
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	0 / 79 (0.00%) 0	4 / 78 (5.13%) 4
Blood creatinine increased subjects affected / exposed occurrences (all)	0 / 79 (0.00%) 0	1 / 79 (1.27%) 1	5 / 78 (6.41%) 9
Neutrophil count decreased subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 7	4 / 79 (5.06%) 12	0 / 78 (0.00%) 0
Weight decreased subjects affected / exposed occurrences (all)	9 / 79 (11.39%) 9	5 / 79 (6.33%) 5	3 / 78 (3.85%) 3
Nervous system disorders			



Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	19 / 79 (24.05%) 22	22 / 79 (27.85%) 30	25 / 78 (32.05%) 33
Dizziness subjects affected / exposed occurrences (all)	8 / 79 (10.13%) 9	9 / 79 (11.39%) 10	6 / 78 (7.69%) 7
Headache subjects affected / exposed occurrences (all)	9 / 79 (11.39%) 10	10 / 79 (12.66%) 11	10 / 78 (12.82%) 15
Paraesthesia subjects affected / exposed occurrences (all)	10 / 79 (12.66%) 12	3 / 79 (3.80%) 4	2 / 78 (2.56%) 2
Peripheral motor neuropathy subjects affected / exposed occurrences (all)	0 / 79 (0.00%) 0	5 / 79 (6.33%) 5	3 / 78 (3.85%) 3
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	12 / 79 (15.19%) 13	24 / 79 (30.38%) 39	27 / 78 (34.62%) 49
Neutropenia subjects affected / exposed occurrences (all)	15 / 79 (18.99%) 42	10 / 79 (12.66%) 39	14 / 78 (17.95%) 32
Leukopenia subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 9	3 / 79 (3.80%) 4	1 / 78 (1.28%) 1
Ear and labyrinth disorders			
Vertigo subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 5	3 / 79 (3.80%) 3	2 / 78 (2.56%) 2
Eye disorders			
Vision blurred subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 4	0 / 79 (0.00%) 0	1 / 78 (1.28%) 1
Gastrointestinal disorders			
Stomatitis subjects affected / exposed occurrences (all)	8 / 79 (10.13%) 10	8 / 79 (10.13%) 10	6 / 78 (7.69%) 11

Nausea			
subjects affected / exposed	45 / 79 (56.96%)	20 / 79 (25.32%)	19 / 78 (24.36%)
occurrences (all)	64	25	27
Haemorrhoids			
subjects affected / exposed	4 / 79 (5.06%)	0 / 79 (0.00%)	1 / 78 (1.28%)
occurrences (all)	5	0	1
Dyspepsia			
subjects affected / exposed	5 / 79 (6.33%)	6 / 79 (7.59%)	5 / 78 (6.41%)
occurrences (all)	5	7	5
Diarrhoea			
subjects affected / exposed	33 / 79 (41.77%)	20 / 79 (25.32%)	30 / 78 (38.46%)
occurrences (all)	54	39	47
Constipation			
subjects affected / exposed	32 / 79 (40.51%)	26 / 79 (32.91%)	21 / 78 (26.92%)
occurrences (all)	45	33	30
Abdominal pain			
subjects affected / exposed	7 / 79 (8.86%)	8 / 79 (10.13%)	3 / 78 (3.85%)
occurrences (all)	8	9	6
Abdominal pain upper			
subjects affected / exposed	3 / 79 (3.80%)	2 / 79 (2.53%)	5 / 78 (6.41%)
occurrences (all)	3	2	6
Vomiting			
subjects affected / exposed	42 / 79 (53.16%)	18 / 79 (22.78%)	10 / 78 (12.82%)
occurrences (all)	73	25	13
Skin and subcutaneous tissue disorders			
Rash erythematous			
subjects affected / exposed	0 / 79 (0.00%)	0 / 79 (0.00%)	4 / 78 (5.13%)
occurrences (all)	0	0	5
Dry skin			
subjects affected / exposed	6 / 79 (7.59%)	3 / 79 (3.80%)	3 / 78 (3.85%)
occurrences (all)	7	4	4
Alopecia			
subjects affected / exposed	25 / 79 (31.65%)	21 / 79 (26.58%)	26 / 78 (33.33%)
occurrences (all)	26	22	26
Rash			

subjects affected / exposed occurrences (all)	0 / 79 (0.00%) 0	1 / 79 (1.27%) 1	4 / 78 (5.13%) 5
Pruritus subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	1 / 79 (1.27%) 1	6 / 78 (7.69%) 9
Pruritus generalised subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	2 / 79 (2.53%) 2	5 / 78 (6.41%) 5
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 79 (0.00%) 0	0 / 79 (0.00%) 0	6 / 78 (7.69%) 6
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	11 / 79 (13.92%) 14	14 / 79 (17.72%) 17	10 / 78 (12.82%) 13
Back pain subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 4	7 / 79 (8.86%) 9	10 / 78 (12.82%) 11
Muscle spasms subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 5	3 / 79 (3.80%) 3	2 / 78 (2.56%) 3
Muscular weakness subjects affected / exposed occurrences (all)	4 / 79 (5.06%) 4	1 / 79 (1.27%) 1	1 / 78 (1.28%) 1
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	3 / 79 (3.80%) 3	1 / 79 (1.27%) 1	5 / 78 (6.41%) 6
Musculoskeletal pain subjects affected / exposed occurrences (all)	7 / 79 (8.86%) 8	5 / 79 (6.33%) 5	8 / 78 (10.26%) 8
Myalgia subjects affected / exposed occurrences (all)	9 / 79 (11.39%) 9	7 / 79 (8.86%) 8	5 / 78 (6.41%) 5
Neck pain			

subjects affected / exposed occurrences (all)	0 / 79 (0.00%) 0	7 / 79 (8.86%) 7	4 / 78 (5.13%) 4
Pain in extremity subjects affected / exposed occurrences (all)	6 / 79 (7.59%) 6	8 / 79 (10.13%) 9	4 / 78 (5.13%) 5
Infections and infestations			
Upper respiratory tract infection subjects affected / exposed occurrences (all)	3 / 79 (3.80%) 4	8 / 79 (10.13%) 9	21 / 78 (26.92%) 40
Respiratory tract infection subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	4 / 79 (5.06%) 4	10 / 78 (12.82%) 14
Oral candidiasis subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 8	4 / 79 (5.06%) 4	3 / 78 (3.85%) 4
Nasopharyngitis subjects affected / exposed occurrences (all)	5 / 79 (6.33%) 7	5 / 79 (6.33%) 6	4 / 78 (5.13%) 4
Lower respiratory tract infection subjects affected / exposed occurrences (all)	1 / 79 (1.27%) 1	3 / 79 (3.80%) 5	12 / 78 (15.38%) 15
Bronchitis subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	4 / 79 (5.06%) 4	2 / 78 (2.56%) 3
Urinary tract infection subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	4 / 79 (5.06%) 4	10 / 78 (12.82%) 18
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	27 / 79 (34.18%) 34	24 / 79 (30.38%) 29	27 / 78 (34.62%) 28
Hypomagnesaemia subjects affected / exposed occurrences (all)	2 / 79 (2.53%) 2	6 / 79 (7.59%) 9	5 / 78 (6.41%) 8
Hyponatraemia			

subjects affected / exposed	1 / 79 (1.27%)	2 / 79 (2.53%)	5 / 78 (6.41%)
occurrences (all)	1	2	5
Hypophosphataemia			
subjects affected / exposed	3 / 79 (3.80%)	4 / 79 (5.06%)	2 / 78 (2.56%)
occurrences (all)	3	5	2

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 June 2014	A
18 July 2014	A
14 April 2016	A
31 May 2016	SA
09 December 2016	A
02 March 2018	A
26 July 2019	A
04 December 2019	A
28 December 2020	A

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported